Abstract
Diagnosis of type 2 diabetes and prediabetes is mandatory. Chronic hyperglycemia in diabetes is associated with long-term micro- and macrovascular as well as with neurological complications. Prediabetes predisposes patients to develop diabetes and macrovascular disease.
Diagnosis of diabetes is established on (at least) one of the following criteria: a fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l), a casual plasma glucose ≥ 200 mg/dl (11.1 mmol/l) in the presence of symptoms, a 2-h plasma glucose during the 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dl (11.1 mmol/l) and/or an HbA1c ≥ 6.5%.
Prediabetes is defined by the Position Statement of the American Diabetes Association as a fasting plasma glucose between 100 and 125 mg/dl (5.6 - 6.9 mmol/l) [a condition called Impaired Fasting Glucose] and/or by a 2-h plasma glucose during OGTT 140 - 199 mg/dl (7.8 - 11.0 mmol) [Impaired Glucose Tolerance] and/or a HbA1c level 5.7 - 6.4%, with however some potential discordance between tests.
The threshold of fasting plasma glucose defining Impaired Fasting Glucose as well as the adequacy of HbA1c as a correct diagnostic tool for prediabetes is still debated.
Keywords: Complications, controversies, definitions, diabetes, prediabetes.
Current Diabetes Reviews
Title:Definitions (and Current Controversies) of Diabetes and Prediabetes
Volume: 12 Issue: 1
Author(s): Martin Buysschaert, Jose-Luis Medina, Benoit Buysschaert and Michael Bergman
Affiliation:
Keywords: Complications, controversies, definitions, diabetes, prediabetes.
Abstract: Diagnosis of type 2 diabetes and prediabetes is mandatory. Chronic hyperglycemia in diabetes is associated with long-term micro- and macrovascular as well as with neurological complications. Prediabetes predisposes patients to develop diabetes and macrovascular disease.
Diagnosis of diabetes is established on (at least) one of the following criteria: a fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l), a casual plasma glucose ≥ 200 mg/dl (11.1 mmol/l) in the presence of symptoms, a 2-h plasma glucose during the 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dl (11.1 mmol/l) and/or an HbA1c ≥ 6.5%.
Prediabetes is defined by the Position Statement of the American Diabetes Association as a fasting plasma glucose between 100 and 125 mg/dl (5.6 - 6.9 mmol/l) [a condition called Impaired Fasting Glucose] and/or by a 2-h plasma glucose during OGTT 140 - 199 mg/dl (7.8 - 11.0 mmol) [Impaired Glucose Tolerance] and/or a HbA1c level 5.7 - 6.4%, with however some potential discordance between tests.
The threshold of fasting plasma glucose defining Impaired Fasting Glucose as well as the adequacy of HbA1c as a correct diagnostic tool for prediabetes is still debated.
Export Options
About this article
Cite this article as:
Buysschaert Martin, Medina Jose-Luis, Buysschaert Benoit and Bergman Michael, Definitions (and Current Controversies) of Diabetes and Prediabetes, Current Diabetes Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573399811666150122150233
DOI https://dx.doi.org/10.2174/1573399811666150122150233 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Analysis of Pyridinium Aldoximes - A Chromatographic Approach
Current Medicinal Chemistry Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery The Use of N-Acetyl Cysteine <i>Versus</i> Chromium Picolinate as an Adjuvant to Clomiphene Citrate and Metformin in PCOS Women to Improve Ovulation Induction and Insulin Resistance: A Pilot Randomized Controlled Trial
Current Women`s Health Reviews Vascular Pleiosynergy - Does It Really Work?
Current Vascular Pharmacology Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Vascular Endothelial Function Change in Elderly Chinese Patients with Obstructive Sleep Apnea and its Association with Coronary Heart Disease
Vascular Disease Prevention (Discontinued) Nonhuman IAPP Variants Inhibit Human IAPP Aggregation
Protein & Peptide Letters Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Mini-Reviews in Medicinal Chemistry Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Current Medicinal Chemistry Differential Gene Expression in the Nucleus Accumbens and Frontal Cortex of Lewis and Fischer 344 Rats Relevant to Drug Addiction
Current Neuropharmacology Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety Access-site Complications of the Transradial Approach: Rare But Still There
Current Cardiology Reviews Improving Peptide Applications Using Nanotechnology
Current Topics in Medicinal Chemistry Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State
Endocrine, Metabolic & Immune Disorders - Drug Targets Comparison of Salivary Antioxidants and Oxidative Stress Status in Gestational Diabetes Mellitus and Healthy Pregnant Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythropoietin and Oxidative Stress
Current Neurovascular Research Structure and Evolution of Human Sirtuins
Current Drug Targets Recent Advances and Challenges in Adipose Tissue Engineering: Adipose Derived Stem Cell-based Approaches
Current Tissue Engineering (Discontinued)